Skip to main content
. 2017 Aug 17;12:140. doi: 10.1186/s13023-017-0692-3

Fig. 2.

Fig. 2

Graphical display of the delayed-start design. At baseline (time 0), patients are randomly assigned to receive either placebo (delayed-start group) or the investigational treatment (early-start group) and they are followed over an extended period of time. Then, patients in the placebo group switch to the investigational treatment until the end of the trial (active treatment phase)